Leptomeningeal disease: current diagnostic and therapeutic strategies

作者：Gautam Nayar, Tiffany Ejikeme, Pakawat Chongsathidkiet, Aladine A. Elsamadicy, Kimberly Blackwell, Jeffrey Clarke, Shivanand P. Lad, Peter E. Fecci · 发表于：Oncotarget · 年份：2017 · DOI：10.18632/oncotarget.20272 · 被引用次数：232 · 研究领域：Brain Metastases and Treatment、Lung Cancer Research Studies、Glioma Diagnosis and Treatment

// Gautam Nayar 1, 2, 3 , Tiffany Ejikeme 1, 2, 3 , Pakawat Chongsathidkiet 1, 2, 6 , Aladine A. Elsamadicy 1, 2, 3 , Kimberly L. Blackwell 4 , Jeffrey M. Clarke 5 , Shivanand P. Lad 3 and Peter E. Fecci 1, 2, 3, 6 1 Duke Brain Tumor Immunotherapy Program, Department of Neurosurgery, Duke University Medical Center, Durham, NC, USA 2 The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA 3 Department of Neurosurgery, Duke University Medical Center, Durham, NC, USA 4 Department of Radiation Oncology, Duke University Medical Center, Durham, NC, USA 5 Division of Medical Oncology, Duke University Medical Center, Durham, NC, USA 6 Department of Pathology, Duke University Medical Center, Durham, NC, USA Correspondence to: Peter E. Fecci, email: Peter.fecci@duke.edu Keywords: leptomeningeal disease, neoplastic meningitis, leptomeningeal carcinomatosis, intrathecal chemotherapy, radiation therapy Received: May 10, 2017 Accepted: July 20, 2017 Published: August 16, 2017 ABSTRACT Leptomeningeal disease has become increasingly prevalent as novel therapeutic interventions extend the survival of cancer patients. Although a majority of leptomeningeal spread occurs secondary to breast cancer, lung cancer, and melanoma, a wide variety of malignancies have been reported as primary sources. Symptoms on presentation are equally diverse, often involving a combination of neurological deficits with the possibility of obstructive hydrocephalus. Diagnosis is def...